市場調查報告書
商品編碼
1017306

生物技術原材料市場:按類型、產品、表達系統:全球機會分析和行業預測(2021-2028)

Biotech Ingredients Market by Type, Product, and Expression Systems : Global Opportunity Analysis and Industry Forecast, 2021-2028

出版日期: | 出版商: Allied Market Research | 英文 300 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

2020年全球生物技術原材料市場規模達到513億美元。

預計從 2021 年到 2028 年,市場將以 4.8% 的複合年增長率增長到 2028 年的 753 億美元。

生物技術成分是由含有天然提取物、精油和生物工程物質的成分組成的化合物。這些化合物存在於動物、植物、微生物和所有天然有機體中。這些複雜的結構是通過雜交瘤和基因工程等過程產生的。

生物技術原材料對合成原材料的需求很高,這對消費群產生了很大的影響。這是由於消費者越來越意識到有機和草藥的健康益處。此外,由於當前的生活方式、壓力和工作習慣引發了各種健康問題並成為仿製藥的驅動因素,因此仿製藥的使用顯著增加。對仿製藥的需求增加也導致更多地轉向使用生物技術成分。此外,食品和飲料行業以及各種膳食補充劑的消費增加也將推動生物技術原料市場的增長。然而,原材料短缺預計將拖累生物技術原材料市場的增長。

本報告調查了生物技術原材料市場,按類型、產品、表達系統、地區和進入市場的公司概況提供了市場概況、趨勢。

目錄

第 1 章介紹

第 2 章執行摘要

第 3 章市場情況

  • 市場定義和範圍
  • 主要調查結果
    • 主要投資領域
  • 波特五力分析
  • 價值鏈分析
  • 市場動態
    • 促進因素
      • 消費者偏好從合成原料到生物基原料的變化
      • 生物科技的發展
    • 抑制因素
      • 原材料供應有限
    • 市場機會
      • 有利的政府政策和生物工程技術進步
  • 專利分析
  • COVID-19 對生物技術原材料市場的影響

第 4 章生物技術原材料市場:按類型

  • 概述
    • 市場規模和預測
  • 藥物活性成分
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
  • 生物仿製藥
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區

第 5 章生物技術原材料市場:按產品

  • 概述
    • 市場規模和預測
  • 單克隆抗體
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
  • 疫苗
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
  • 激素和生長因子
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
  • 細胞因子
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
  • 融合蛋白
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
  • 治療□
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
  • 血液因子
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區

第 6 章生物技術原材料市場:按表達系統

  • 概述
    • 市場規模和預測
  • 哺乳動物表達系統
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
  • 微生物表達系統
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
  • 酵母表達系統
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
  • 植物表達系統
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
  • 昆蟲表達系統
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區

第 7 章生物技術原材料市場:按地區

  • 概述
    • 市場規模和預測
  • 北美
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按類型
    • 市場規模和預測:按產品分類
    • 市場規模和預測:按表達系統
    • 市場規模和預測:按國家/地區
    • 美國
      • 市場規模和預測:按類型
      • 市場規模和預測:按產品分類
      • 市場規模和預測:按表達系統
    • 加拿大
      • 市場規模和預測:按類型
      • 市場規模和預測:按產品分類
      • 市場規模和預測:按表達系統
    • 墨西哥
      • 市場規模和預測:按類型
      • 市場規模和預測:按產品分類
      • 市場規模和預測:按表達系統
  • 歐洲
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按類型
    • 市場規模和預測:按產品分類
    • 市場規模和預測:按表達系統
    • 市場份額分析:按國家/地區
    • 德國
      • 市場規模和預測:按類型
      • 市場規模和預測:按產品分類
      • 市場規模和預測:按表達系統
    • 英國
      • 市場規模和預測:按類型
      • 市場規模和預測:按產品分類
      • 市場規模和預測:按表達系統
    • 法國
      • 市場規模和預測:按類型
      • 市場規模和預測:按產品分類
      • 市場規模和預測:按表達系統
    • 意大利
      • 市場規模和預測:按類型
      • 市場規模和預測:按產品分類
      • 市場規模和預測:按表達系統
    • 西班牙
      • 市場規模和預測:按類型
      • 市場規模和預測:按產品分類
      • 市場規模和預測:按表達系統
    • 其他歐洲
      • 市場規模和預測:按類型
      • 市場規模和預測:按產品分類
      • 市場規模和預測:按表達系統
  • 亞太地區
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按類型
    • 市場規模和預測:按產品分類
    • 市場規模和預測:按表達系統
    • 市場份額分析:按國家/地區
    • 中國
      • 市場規模和預測:按類型
      • 市場規模和預測:按產品分類
      • 市場規模和預測:按表達系統
    • 日本
      • 市場規模和預測:按類型
      • 市場規模和預測:按產品分類
      • 市場規模和預測:按表達系統
    • 印度
      • 市場規模和預測:按類型
      • 市場規模和預測:按產品分類
      • 市場規模和預測:按表達系統
    • 韓國
      • 市場規模和預測:按類型
      • 市場規模和預測:按產品分類
      • 市場規模和預測:按表達系統
    • 澳大利亞
      • 市場規模和預測:按類型
      • 市場規模和預測:按產品分類
      • 市場規模和預測:按表達系統
    • 其他亞太地區
      • 市場規模和預測:按類型
      • 市場規模和預測:按產品分類
      • 市場規模和預測:按表達系統
  • 拉美亞
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按類型
    • 市場規模和預測:按產品分類
    • 市場規模和預測:按表達系統
    • 市場份額分析:按國家/地區
    • 巴西
      • 市場規模和預測:按類型
      • 市場規模和預測:按產品分類
      • 市場規模和預測:按表達系統
    • 沙特阿拉伯
      • 市場規模和預測:按類型
      • 市場規模和預測:按產品分類
      • 市場規模和預測:按表達系統
    • 南非
      • 市場規模和預測:按類型
      • 市場規模和預測:按產品分類
      • 市場規模和預測:按表達系統
    • 其他 LAMEA
      • 市場規模和預測:按類型
      • 市場規模和預測:按產品分類
      • 市場規模和預測:按表達系統

第 8 章競爭形勢

  • 簡介
    • 2020年市場參與者定位
  • 主要成功策略
    • 主要成功策略:按年
    • 主要成功策略:靠發展
    • 主要成功策略:按公司分類
  • 主要開發
    • 收購
    • 推出新產品

第 9 章公司簡介

  • AstraZeneca plc
  • Merck & Co.
  • Abbvie
  • MYLAN N.V.
  • NOVARTIS INTERNATIONAL AG
  • PFIZER INC.
  • SANOFI S.A.
  • Boehringer Ingelheim
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • ELI LILLY AND COMPANY
目錄
Product Code: A11345

The global biotech ingredient market was valued at $51.3 billion in 2020, and is anticipated to generate $75.3 billion by 2028. The market is projected to experience growth at a CAGR of 4.8% from 2021 to 2028.

Biotech ingredients are compounds that consist of components with natural extracts, essential oils, and bio-engineered substances. These compounds are found in animals, plants, micro-organisms, and any natural living organisms. These complex structures are produced through processes such as hybridoma and genetic engineering.

Biotech ingredients are experiencing high demand over synthetic ingredients marking a huge shift in consumer base. This is attributed to rise in awareness among consumers regarding health benefits from organic and herbal medicines. Moreover, use of generic medicines has also increased significantly as current lifestyles, stress, and working habits have led to various health concerns, which acts as a driving factor for generic medicines. Increase in demand for generic medicines have also led to increase in shift toward use of biotech ingredients. In addition, rise in consumption in the food & beverages industry and various health supplements also drive growth of the biotech ingredients market growth. However, unavailability of raw materials acts as restraint for the biotech ingredients market growth.

The biotech ingredient market is segmented on the basis of type, product, application, and region. Depending on type, the market is segmented into active pharmaceutical ingredients (API) and biosimilars. By product, it is categorized into monoclonal antibodies, vaccines, hormones & growth factors, cytokines, fusion proteins, therapeutic enzymes, and blood factors. By expression systems, it is divided into mammalian expression systems, microbial expression systems, yeast expression systems, plant expression systems, and insect expression systems. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA (Latin America, Middle East, and Africa).

The key players operating in the market are Pfizer Inc., Novartis International AG, Merck & Co., Teva Pharmaceutical Industries Ltd., Mylan, Inc., Boehringer Ingelheim, Sanofi, AbbVie, Eli Lilly and Company, and AstraZeneca plc. The players in the market have adopted several strategies, such as type launch and business expansion, to sustain the market competition.

KEY BENEFITS FOR STAKEHOLDERS

  • The report provides extensive qualitative and quantitative analysis of the current trends and future estimations of the biotech ingredients market from 2020 to 2027 to determine the prevailing opportunities.
  • Comprehensive analysis of factors that drive and restrict the market growth is provided.
  • The biotech ingredients market forecast and estimations are based on factors impacting the market growth, in terms of value.
  • Profiles of leading players operating in the market are provided to understand the global competitive scenario.
  • The report provides extensive qualitative insights on the significant segments and regions exhibiting favorable biotech ingredients market share.
  • The biotech ingredients market size is provided in terms of revenue.
  • The report provides an in-depth analysis of the forecast along with the current and future biotech ingredients market trends.

KEY MARKET SEGMENTS

By Type

  • Active Pharmaceutical Ingredients
  • Biosimilars

By Product

  • Monoclonal Antibodies
  • Vaccines
  • Hormones and Growth Factors
  • Cytokines
  • Fusion Proteins
  • Therapeutic Enzymes
  • Blood Factors

By Expression Systems

  • Mammalian Expression Systems
  • Microbial Expression Systems
  • Yeast Expression Systems
  • Plant Expression Systems
  • Insect Expression Systems

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • South Africa
  • Saudi Arabia
  • Rest of LAMEA
  • Key Players
  • Pfizer Inc.
  • Novartis International AG
  • Merck & Co.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan, Inc.
  • Boehringer Ingelheim
  • Sanofi
  • AbbVie
  • Eli Lilly and Company
  • AstraZeneca plc

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
  • 1.4.Research methodology
    • 1.4.1.Primary research
    • 1.4.2.Secondary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Value chain analysis
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Shift in consumer preference from synthetic to bio-based ingredients
      • 3.5.1.2.Development in biotechnology
    • 3.5.2.Restraint
      • 3.5.2.1.Limited availability of raw material
    • 3.5.3.Opportunity
      • 3.5.3.1.Favorable government policies and technological advancements in bio-engineering
  • 3.6.Patent analysis
  • 3.7.Impact of COVID-19 on the biotech ingredients market

CHAPTER 4:BIOTECH INGREDIENTS MARKET, BY TYPE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Active pharmaceutical ingredients
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
  • 4.3.Biosimilars
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region

CHAPTER 5:BIOTECH INGREDIENTS MARKET, BY PRODUCT

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Monoclonal antibodies
    • 5.2.1.Key market trends, growth factors, and opportunities
    • 5.2.2.Market size and forecast, by region
  • 5.3.Vaccines
    • 5.3.1.Key market trends, growth factors, and opportunities
    • 5.3.2.Market size and forecast, by region
  • 5.4.Hormones & growth factors
    • 5.4.1.Key market trends, growth factors, and opportunities
    • 5.4.2.Market size and forecast, by region
  • 5.5.Cytokines
    • 5.5.1.Key market trends, growth factors, and opportunities
    • 5.5.2.Market size and forecast, by region
  • 5.6.Fusion proteins
    • 5.6.1.Key market trends, growth factors, and opportunities
    • 5.6.2.Market size and forecast, by region
  • 5.7.Therapeutic enzymes
    • 5.7.1.Key market trends, growth factors, and opportunities
    • 5.7.2.Market size and forecast, by region
  • 5.8.Blood factors
    • 5.8.1.Key market trends, growth factors, and opportunities
    • 5.8.2.Market size and forecast, by region

CHAPTER 6:BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Mammalian expression systems
    • 6.2.1.Key market trends, growth factors, and opportunities
    • 6.2.2.Market size and forecast, by region
  • 6.3.Microbial expression systems
    • 6.3.1.Key market trends, growth factors, and opportunities
    • 6.3.2.Market size and forecast, by region
  • 6.4.Yeast Expression Systems
    • 6.4.1.Key market trends, growth factors, and opportunities
    • 6.4.2.Market size and forecast, by region
  • 6.5.Plant Expression Systems
    • 6.5.1.Key market trends, growth factors, and opportunities
    • 6.5.2.Market size and forecast, by region
  • 6.6.Insect expression systems
    • 6.6.1.Key market trends, growth factors, and opportunities
    • 6.6.2.Market size and forecast, by region

CHAPTER 7:BIOTECH INGREDIENTS MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends, growth factors, and opportunities
    • 7.2.2.Market size and forecast, by type
    • 7.2.3.Market size and forecast, by product
    • 7.2.4.Market size and forecast, by expression systems
    • 7.2.5.Market size and forecast, by country
    • 7.2.6.U.S.
      • 7.2.6.1.Market size and forecast, by type
      • 7.2.6.2.Market size and forecast, by product
      • 7.2.6.3.Market size and forecast, by expression systems
    • 7.2.7.Canada
      • 7.2.7.1.Market size and forecast, by type
      • 7.2.7.2.Market size and forecast, by product
      • 7.2.7.3.Market size and forecast, by expression systems
    • 7.2.8.Mexico
      • 7.2.8.1.Market size and forecast, by type
      • 7.2.8.2.Market size and forecast, by product
      • 7.2.8.3.Market size and forecast, by expression systems
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Market size and forecast, by type
    • 7.3.3.Market size and forecast, by product
    • 7.3.4.Market size and forecast, by expression systems
    • 7.3.5.Market share analysis, by country
    • 7.3.6.Germany
      • 7.3.6.1.Market size and forecast, by type
      • 7.3.6.2.Market size and forecast, by product
      • 7.3.6.3.Market size and forecast, by expression systems
    • 7.3.7.UK
      • 7.3.7.1.Market size and forecast, by type
      • 7.3.7.2.Market size and forecast, by product
      • 7.3.7.3.Market size and forecast, by expression systems
    • 7.3.8.France
      • 7.3.8.1.Market size and forecast, by type
      • 7.3.8.2.Market size and forecast, by product
      • 7.3.8.3.Market size and forecast, by expression systems
    • 7.3.9.Italy
      • 7.3.9.1.Market size and forecast, by type
      • 7.3.9.2.Market size and forecast, by product
      • 7.3.9.3.Market size and forecast, by expression systems
    • 7.3.10.Spain
      • 7.3.10.1.Market size and forecast, by type
      • 7.3.10.2. Market size and forecast, by product
      • 7.3.10.3. Market size and forecast, by expression systems
    • 7.3.11.Rest of Europe
      • 7.3.11.1. Market size and forecast, by type
      • 7.3.11.2. Market size and forecast, by product
      • 7.3.11.3.Market size and forecast, by expression systems
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Market size and forecast, by type
    • 7.4.3.Market size and forecast, by product
    • 7.4.4.Market size and forecast, by expression systems
    • 7.4.5.Market share analysis, by country
    • 7.4.6.China
      • 7.4.6.1.Market size and forecast, by type
      • 7.4.6.2.Market size and forecast, by product
      • 7.4.6.3.Market size and forecast, by expression systems
    • 7.4.7.Japan
      • 7.4.7.1.Market size and forecast, by type
      • 7.4.7.2.Market size and forecast, by product
      • 7.4.7.3.Market size and forecast, by expression systems
    • 7.4.8.India
      • 7.4.8.1.Market size and forecast, by type
      • 7.4.8.2.Market size and forecast, by product
      • 7.4.8.3.Market size and forecast, by expression systems
    • 7.4.9.South Korea
      • 7.4.9.1.Market size and forecast, by type
      • 7.4.9.2.Market size and forecast, by product
      • 7.4.9.3.Market size and forecast, by expression systems
    • 7.4.10.Australia
      • 7.4.10.1.Market size and forecast, by type
      • 7.4.10.2.Market size and forecast, by product
      • 7.4.10.3.Market size and forecast, by expression systems
    • 7.4.11.Rest of Asia-Pacific
      • 7.4.11.1.Market size and forecast, by type
      • 7.4.11.2.Market size and forecast, by product
      • 7.4.11.3.Market size and forecast, by expression systems
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.Market size and forecast, by type
    • 7.5.3.Market size and forecast, by product
    • 7.5.4.Market size and forecast, by expression systems
    • 7.5.5.Market share analysis, by country
    • 7.5.6.Brazil
      • 7.5.6.1.Market size and forecast, by type
      • 7.5.6.2.Market size and forecast, by product
      • 7.5.6.3.Market size and forecast, by expression systems
    • 7.5.7.Saudi Arabia
      • 7.5.7.1.Market size and forecast, by type
      • 7.5.7.2.Market size and forecast, by product
      • 7.5.7.3.Market size and forecast, by expression systems
    • 7.5.8.South Africa
      • 7.5.8.1.Market size and forecast, by type
      • 7.5.8.2.Market size and forecast, by product
      • 7.5.8.3.Market size and forecast, by expression systems
    • 7.5.9.Rest of LAMEA
      • 7.5.9.1.Market size and forecast, by type
      • 7.5.9.2.Market size and forecast, by product
      • 7.5.9.3.Market size and forecast, by expression systems

CHAPTER 8:COMPETITIVE LANDSCAPE

  • 8.1.Introduction
    • 8.1.1.Market player positioning, 2020
  • 8.2.Top winning strategies
    • 8.2.1.Top winning strategies, by year
    • 8.2.2.Top winning strategies, by development
    • 8.2.3.Top winning strategies, by company
  • 8.3.Key developments
    • 8.3.1.Acquisitions
    • 8.3.2.New Product launches

CHAPTER 9:COMPANY PROFILES

  • 9.1.AstraZeneca plc
    • 9.1.1.Company overview
    • 9.1.2.Company snapshot
    • 9.1.3.Operating Segments
    • 9.1.4.Product portfolio
    • 9.1.5.Business performance
  • 9.2.Merck & Co.
    • 9.2.1.Company overview
    • 9.2.2.Company snapshot
    • 9.2.3.Operating Segments
    • 9.2.4.Product portfolio
    • 9.2.5.Business performance
  • 9.3.Abbvie
    • 9.3.1.Company overview
    • 9.3.2.Company snapshot
    • 9.3.3.Product portfolio
    • 9.3.4.Business performance
    • 9.3.5.Key Developmental strategies
  • 9.4.MYLAN N.V.
    • 9.4.1.Company overview
    • 9.4.2.Company snapshot
    • 9.4.3.Type portfolio
    • 9.4.4.Business performance
    • 9.4.5.Key Developmental strategies
  • 9.5.NOVARTIS INTERNATIONAL AG
    • 9.5.1.Company overview
    • 9.5.2.Company snapshot
    • 9.5.3.Operating business segments
    • 9.5.4.Type portfolio
    • 9.5.5.Business performance
  • 9.6.PFIZER INC.
    • 9.6.1.Company overview
    • 9.6.2.Company snapshot
    • 9.6.3.Operating business segments
    • 9.6.4.Type portfolio
    • 9.6.5.Business performance
  • 9.7.SANOFI S.A.
    • 9.7.1.Company overview
    • 9.7.2.Company snapshot
    • 9.7.3.Operating business segments
    • 9.7.4.Type portfolio
    • 9.7.5.Business performance
  • 9.8.Boehringer Ingelheim
    • 9.8.1.Company overview
    • 9.8.2.Company snapshot
    • 9.8.3.Product portfolio
  • 9.9.TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 9.9.1.Company overview
    • 9.9.2.Company snapshot
    • 9.9.3.Type portfolio
    • 9.9.4.Business performance
  • 9.10.ELI LILLY AND COMPANY
    • 9.10.1.Company overview
    • 9.10.2.Company snapshot
    • 9.10.3.Product portfolio
    • 9.10.4.Business performance

LIST OF TABLES

  • TABLE 01.GLOBAL BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILLION)
  • TABLE 02.ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 03.BIOSIMILARS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 04.GLOBAL BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 05.MONOCLONAL ANTIBODIES BIOTECH INGREDIENTS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 06.VACCINES BIOTECH INGREDIENTS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 07.HORMONES & GROWTH FACTORS BIOTECH INGREDIENTS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 08.CYTOKINES BIOTECH INGREDIENTS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 09.FUSION PROTEINS BIOTECH INGREDIENTS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 10.THERAPEUTIC ENZYMES BIOTECH INGREDIENTS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 11.BLOOD FACTORS BIOTECH INGREDIENTS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 12.GLOBAL BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILLION)
  • TABLE 13.BIOTECH INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2020-2028 ($MILLION)
  • TABLE 14.BIOTECH INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY REGION, 2020-2028 ($MILLION)
  • TABLE 15.BIOTECH INGREDIENTS MARKET, FOR YEAST EXPRESSION SYSTEMS, BY REGION, 2020-2028 ($MILLION)
  • TABLE 16.BIOTECH INGREDIENTS MARKET FOR PLANT EXPRESSION SYSTEMS, BY REGION, 2020-2028 ($MILLION)
  • TABLE 17.BIOTECH INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY REGION, 2020-2028 ($MILLION)
  • TABLE 18.BIOTECH INGREDIENTS MARKET, BY REGION, 2020--2028 ($MILLION)
  • TABLE 19.NORTH AMERICA BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILLION)
  • TABLE 20.NORTH AMERICA BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 21.NORTH AMERICA BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILLION)
  • TABLE 22.NORTH AMERICA BIOTECH INGREDIENTS MARKET, BY COUNTRY, 2020-2028 ($MILLION)
  • TABLE 23.U.S. BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILLION)
  • TABLE 24.U.S. BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 25.U.S. BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILLION)
  • TABLE 26.CANADA BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILLION)
  • TABLE 27.CANADA BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 28.CANADA BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILLION)
  • TABLE 29.MEXICO BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILLION)
  • TABLE 30.MEXICO BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 31.MEXICO BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILLION)
  • TABLE 32.EUROPE BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILLION)
  • TABLE 33.EUROPE BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 34.EUROPE BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILLION)
  • TABLE 35.EUROPE BIOTECH INGREDIENTS MARKET, BY COUNTRY, 2020-2028 ($MILLION)
  • TABLE 36.GERMANY BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILLION)
  • TABLE 37.GERMANY BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 38.GERMANY BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILLION)
  • TABLE 39.UK BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILLION)
  • TABLE 40.UK BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 41.UK BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILLION)
  • TABLE 42.FRANCE BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILLION)
  • TABLE 43.FRANCE BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 44.FRANCE BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILLION)
  • TABLE 45.ITALY BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILLION)
  • TABLE 46.ITALY BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 47.ITALY BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILLION)
  • TABLE 48.SPAIN BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILLION)
  • TABLE 49.SPAIN BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 50.SPAIN BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILLION)
  • TABLE 51.REST OF EUROPE BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILLION)
  • TABLE 52.REST OF EUROPE BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 53.REST OF EUROPE BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILLION)
  • TABLE 54.ASIA-PACIFIC BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILLION)
  • TABLE 55.ASIA-PACIFIC BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 56.ASIA-PACIFIC BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILLION)
  • TABLE 57.ASIA-PACIFIC BIOTECH INGREDIENTS MARKET, BY COUNTRY, 2020-2028 ($MILLION)
  • TABLE 58.CHINA BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILLION)
  • TABLE 59.CHINA BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 60.CHINA BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILLION)
  • TABLE 61.JAPAN BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILLION)
  • TABLE 62.JAPAN BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 63.JAPAN BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILLION)
  • TABLE 64.INDIA BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILLION)
  • TABLE 65.INDIA BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 66.INDIA BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILLION)
  • TABLE 67.SOUTH KOREA BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILLION)
  • TABLE 68.SOUTH KOREA BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 69.SOUTH KOREA BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILLION)
  • TABLE 70.AUSTRALIA BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILLION)
  • TABLE 71.AUSTRALIA BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 72.AUSTRALIA BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILLION)
  • TABLE 73.REST OF ASIA-PACIFIC BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILLION)
  • TABLE 74.REST OF ASIA-PACIFIC BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 75.REST OF ASIA-PACIFIC BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILLION)
  • TABLE 76.LAMEA BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILLION)
  • TABLE 77.LAMEA BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 78.LAMEA BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILLION)
  • TABLE 79.LAMEA BIOTECH INGREDIENTS MARKET, BY COUNTRY, 2020-2028 ($MILLION)
  • TABLE 80.BRAZIL BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILLION)
  • TABLE 81.BRAZIL BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 82.BRAZIL BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILLION)
  • TABLE 83.SAUDI ARABIA BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILLION)
  • TABLE 84.SAUDI ARABIA BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 85.SAUDI ARABIA BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILLION)
  • TABLE 86.SOUTH AFRICA BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILLION)
  • TABLE 87.SOUTH AFRICA BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 88.SOUTH AFRICA BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILLION)
  • TABLE 89.REST OF LAMEA BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILLION)
  • TABLE 90.REST OF LAMEA BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 91.REST OF LAMEA BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILLION)
  • TABLE 92.KEY ACQUISITION (2017-2021)
  • TABLE 93.NEW PRODUCT LAUNCHES (2017-2021)
  • TABLE 94.ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 95.ASTRAZENECA: OPERTAING SEGMENTS
  • TABLE 96.ZYDUS CADILA: PRODUCT PORTFOLIO
  • TABLE 97.OVERALL FINANCIAL STATUS ($MILLION)
  • TABLE 98.MERCK & CO.: COMPANY SNAPSHOT
  • TABLE 99.MERCK & CO.: OPERTAING SEGMENTS
  • TABLE 100.MERCK & CO.: PRODUCT PORTFOLIO
  • TABLE 101.OVERALL FINANCIAL STATUS ($MILLION)
  • TABLE 102.ABBVIE: COMPANY SNAPSHOT
  • TABLE 103.ABBVIE: PRODUCT PORTFOLIO
  • TABLE 104.OVERALL FINANCIAL STATUS ($MILLION)
  • TABLE 105.ABBVIE: KEY DEVELOPMENTAL STRATEGIES
  • TABLE 106.MYLAN: COMPANY SNAPSHOT
  • TABLE 107.MYLAN: PRODUCT PORTFOLIO
  • TABLE 108.OVERALL FINANCIAL STATUS ($MILLION)
  • TABLE 109.MYLAN: PRODUCT PORTFOLIO
  • TABLE 110.NOVARTIS: COMPANY SNAPSHOT
  • TABLE 111.NOVARTIS: OPERATING SEGMENTS
  • TABLE 112.NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 113.OVERALL FINANCIAL STATUS ($MILLION)
  • TABLE 114.PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 115.PFIZER INC.: OPERATING SEGMENTS
  • TABLE 116.PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 117.OVERALL FINANCIAL STATUS ($MILLION)
  • TABLE 118.SANOFI: COMPANY SNAPSHOT
  • TABLE 119.SANOFI: OPERATING SEGMENTS
  • TABLE 120.SANOFI: PRODUCT PORTFOLIO
  • TABLE 121.OVERALL FINANCIAL STATUS ($MILLION)
  • TABLE 122.BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
  • TABLE 123.BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
  • TABLE 124.TEVA: COMPANY SNAPSHOT
  • TABLE 125.TEVA: PRODUCT PORTFOLIO
  • TABLE 126.OVERALL FINANCIAL STATUS ($MILLION)
  • TABLE 127.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 128.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 129.OVERALL FINANCIAL STATUS ($MILLION)

LIST OF FIGURES

  • FIGURE 01.KEY MARKET SEGMENTS
  • FIGURE 02.GLOBAL BIOTECH INGREDIENTS MARKET SNAPSHOT, BY SEGMENTATION, 2020-2028
  • FIGURE 03.BIOTECH INGREDIENTS MARKET SNAPSHOT, BY COUNTRY, 2020-2028
  • FIGURE 04.TOP INVESTMENT POCKETS
  • FIGURE 05.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 06.HIGH THREAT OF NEW ENTRANTS
  • FIGURE 07.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 08.LOW INTENSITY OF RIVALRY
  • FIGURE 09.HIGH BARGAINING POWER OF BUYERS
  • FIGURE 10.VALUE CHAIN ANALYSIS FOR BIOTECH INGREDIENTS MARKET
  • FIGURE 11.BIOTECH INGREDIENTS MARKET DYNAMICS
  • FIGURE 12.BIOTECH INGREDIENTS PATENT ANALYSIS
  • FIGURE 13.GLOBAL BIOTECH INGREDIENTS MARKET, BY TYPE, 2020-2028 ($MILILION)
  • FIGURE 14.COMPARATIVE ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 15.COMPARATIVE ANALYSIS OF PEM BIOTECH INGREDIENTS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 16.GLOBAL BIOTECH INGREDIENTS MARKET, BY PRODUCT, 2020-2028 ($MILILION)
  • FIGURE 17.COMPARATIVE ANALYSIS OF MONOCLONAL ANTIBODIES BIOTECH INGREDIENTS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 18.COMPARATIVE ANALYSIS OF VACCINES BIOTECH INGREDIENTS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 19.COMPARATIVE ANALYSIS OF HORMONES & GROWTH FACTORS BIOTECH INGREDIENTS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 20.COMPARATIVE ANALYSIS OF CYTOKINES BIOTECH INGREDIENTS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 21.COMPARATIVE ANALYSIS OF FUSION PROTEINS BIOTECH INGREDIENTS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 22.COMPARATIVE ANALYSIS OF THERAPEUTIC ENZYMES BIOTECH INGREDIENTS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 23.COMPARATIVE ANALYSIS OF BLOOD FACTORS BIOTECH INGREDIENTS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 24.GLOBAL BIOTECH INGREDIENTS MARKET, BY EXPRESSION SYSTEMS, 2020-2028 ($MILILION)
  • FIGURE 25.COMPARATIVE ANALYSIS OF BIOTECH INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 26.COMPARATIVE ANALYSIS OF BIOTECH INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 27.COMPARATIVE ANALYSIS OF BIOTECH INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 28.COMPARATIVE ANALYSIS OF BIOTECH INGREDIENTS MARKET FOR PLANT EXPRESSION SYSTEMS, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 29.COMPARATIVE ANALYSIS OF BIOTECH INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 30.U.S. BIOTECH INGREDIENTS MARKET REVENUE, 2020-2028 (MILLION)
  • FIGURE 31.CANADA BIOTECH INGREDIENTS MARKET REVENUE, 2020-2028 (MILLION)
  • FIGURE 32.MEXICO BIOTECH INGREDIENTS MARKET REVENUE, 2020-2028 (MILLION)
  • FIGURE 33.GERMANY BIOTECH INGREDIENTS MARKET REVENUE, 2020-2028 (MILLION)
  • FIGURE 34.UK BIOTECH INGREDIENTS MARKET REVENUE, 2020-2028 (MILLION)
  • FIGURE 35.FRANCE BIOTECH INGREDIENTS MARKET REVENUE, 2020-2028 (MILLION)
  • FIGURE 36.ITALY BIOTECH INGREDIENTS MARKET REVENUE, 2020-2028 (MILLION)
  • FIGURE 37.SPAIN BIOTECH INGREDIENTS MARKET REVENUE, 2020-2028 (MILLION)
  • FIGURE 38.REST OF EUROPE BIOTECH INGREDIENTS MARKET REVENUE, 2020-2028 (MILLION)
  • FIGURE 39.CHINA BIOTECH INGREDIENTS MARKET REVENUE, 2020-2028 (MILLION)
  • FIGURE 40.JAPAN BIOTECH INGREDIENTS MARKET REVENUE, 2020-2028 (MILLION)
  • FIGURE 41.INDIA BIOTECH INGREDIENTS MARKET REVENUE, 2020-2028 (MILLION)
  • FIGURE 42.SOUTH KOREA BIOTECH INGREDIENTS MARKET REVENUE, 2020-2028 (MILLION)
  • FIGURE 43.AUSTRALIA BIOTECH INGREDIENTS MARKET REVENUE, 2020-2028 (MILLION)
  • FIGURE 44.REST OF ASIA-PACIFIC BIOTECH INGREDIENTS MARKET REVENUE, 2020-2028 (MILLION)
  • FIGURE 45.BRAZIL BIOTECH INGREDIENTS MARKET REVENUE, 2020-2028 (MILLION)
  • FIGURE 46.SAUDI ARABIA BIOTECH INGREDIENTS MARKET REVENUE, 2020-2028 (MILLION)
  • FIGURE 47.SOUTH AFRICA BIOTECH INGREDIENTS MARKET REVENUE, 2020-2028 (MILLION)
  • FIGURE 48.REST OF LAMEA BIOTECH INGREDIENTS MARKET REVENUE, 2020-2028 (MILLION)
  • FIGURE 49.MARKET PLAYER POSITIONING, 2020
  • FIGURE 50.TOP WINNING STRATEGIES, BY YEAR, 2017-2021
  • FIGURE 51.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017-2021 (%)
  • FIGURE 52.TOP WINNING STRATEGIES, BY COMPANY, 2017-2021
  • FIGURE 53.ASTRAZENECA: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 54.ASTRAZENECA: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 55.ASTRAZENECA: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 56.MERCK & CO.: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 57.MERCK & CO.: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 58.MERCK & CO.: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 59.ABBVIE: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 60.ABBVIE: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 61.ABBVIE: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 62.MYLAN: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 63.MYLAN: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 64.MYLAN: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 65.MYLAN: REVENUE SHARE BY COUNTRY OF SUBSIDIARIES, 2019 (%)
  • FIGURE 66.KOBE: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 67.NOVARTIS: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 68.NOVARTIS: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 69.NOVARTIS: REVENUE SHARE BY DIVISION, 2019 (%)
  • FIGURE 70.PFIZER INC.: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 71.PFIZER INC.: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 72.PFIZER INC.: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 73.SANOFI: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 74.SANOFI: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 75.SANOFI: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 76.TEVA: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 77.TEVA: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 78.ELI LILLY AND COMPANY: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 79.ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2019 (%)